To investigate whether CXCR4 antagonism can correct peripheral blood neutropenia, a common clinical phenotype observed in patients with CXCR2 LOF variants (22–25), we initially considered using Cxcr2 knockout (Cxcr2-/-) mice. Here, CXCR4 is linked to neutropenia.